Cost-effectiveness of preparticipation screening for prevention of sudden cardiac death in young athletes.

BACKGROUND

Inclusion of 12-lead electrocardiography (ECG) in preparticipation screening of young athletes is controversial because of concerns about cost-effectiveness.

OBJECTIVE

To evaluate the cost-effectiveness of ECG plus cardiovascular-focused history and physical examination compared with cardiovascular-focused history and physical examination alone for preparticipation screening.

DESIGN

Decision-analysis, cost-effectiveness model.

DATA SOURCES

Published epidemiologic and preparticipation screening data, vital statistics, and other publicly available data.

TARGET POPULATION

Competitive athletes in high school and college aged 14 to 22 years.

TIME HORIZON

Lifetime.

PERSPECTIVE

Societal.

INTERVENTION

Nonparticipation in competitive athletic activity and disease-specific treatment for identified athletes with heart disease.

OUTCOME MEASURE

Incremental health care cost per life-year gained.

RESULTS OF BASE-CASE ANALYSIS: Addition of ECG to preparticipation screening saves 2.06 life-years per 1000 athletes at an incremental total cost of $89 per athlete and yields a cost-effectiveness ratio of $42 900 per life-year saved (95% CI, $21 200 to $71 300 per life-year saved) compared with cardiovascular-focused history and physical examination alone. Compared with no screening, ECG plus cardiovascular-focused history and physical examination saves 2.6 life-years per 1000 athletes screened and costs $199 per athlete, yielding a cost-effectiveness ratio of $76 100 per life-year saved ($62 400 to $130 000).

RESULTS OF SENSITIVITY ANALYSIS

Results are sensitive to the relative risk reduction associated with nonparticipation and the cost of initial screening.

LIMITATIONS

Effectiveness data are derived from 1 major European study. Patterns of causes of sudden death may vary among countries.

CONCLUSION

Screening young athletes with 12-lead ECG plus cardiovascular-focused history and physical examination may be cost-effective.

PRIMARY FUNDING SOURCE

Stanford Cardiovascular Institute and the Breetwor Foundation.